Mubritinib

Mubritinib

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole
CAS Number	366017-09-6
PubChem CID	6444692
IUPHAR/BPS	6011
ChemSpider	4948554
UNII	V734AZP9BR
ChEMBL	CHEMBL1614707
Chemical and physical data
Formula	C25H23F3N4O2
Molar mass	468.47 g/mol
3D model (JSmol)	Interactive image
SMILES FC(F)(F)c1ccc(cc1)\C=C\c2nc(co2)COc3ccc(cc3)CCCCn4nncc4

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.